

09/ 895,975

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAY 01	New CAS web site launched
NEWS	3	MAY 08	CA/CAPplus Indian patent publication number format defined
NEWS	4	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	5	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	6	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	7	MAY 21	CA/CAPplus enhanced with additional kind codes for German patents
NEWS	8	MAY 22	CA/CAPplus enhanced with IPC reclassification in Japanese patents
NEWS	9	JUN 27	CA/CAPplus enhanced with pre-1967 CAS Registry Numbers
NEWS	10	JUN 29	STN Viewer now available
NEWS	11	JUN 29	STN Express, Version 8.2, now available
NEWS	12	JUL 02	LEMBASE coverage updated
NEWS	13	JUL 02	LMEDLINE coverage updated
NEWS	14	JUL 02	SCISEARCH enhanced with complete author names
NEWS	15	JUL 02	CHEMCATS accession numbers revised
NEWS	16	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS	17	JUL 16	CAPplus enhanced with French and German abstracts
NEWS	18	JUL 18	CA/CAPplus patent coverage enhanced
NEWS	19	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	20	JUL 30	USGENE now available on STN
NEWS	21	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	22	AUG 06	BEILSTEIN updated with new compounds
NEWS	23	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	24	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	25	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	26	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	27	AUG 27	USPATOLD now available on STN
NEWS	28	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS EXPRESS	29	JUNE 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

09/ 895,975

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:44:30 ON 28 AUG 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:44:57 ON 28 AUG 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 AUG 2007 HIGHEST RN 945649-99-0

DICTIONARY FILE UPDATES: 27 AUG 2007 HIGHEST RN 945649-99-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\09895975.str



chain nodes :

10

ring nodes :

1 2 3 4 5 6 7 8 9 11 12 13 14 15 16

chain bonds :

4-10 5-11

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 11-12 11-16 12-13 13-14 14-15  
15-16

09/ 895,975

exact/norm bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 4-10 5-6 7-8 8-9

exact bonds :

5-11

normalized bonds :

11-12 11-16 12-13 13-14 14-15 15-16

isolated ring systems :

containing 1 : 11 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS


11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 14:45:19 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 292 TO ITERATE

100.0% PROCESSED 292 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 4815 TO 6865

PROJECTED ANSWERS: 1986 TO 3374

L2 50 SEA SSS SAM L1

=> s 11 ful

FULL SEARCH INITIATED 14:45:29 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 5833 TO ITERATE

100.0% PROCESSED 5833 ITERATIONS

2632 ANSWERS

SEARCH TIME: 00.00.01

L3 2632 SEA SSS FUL L1

09/ 895,975

=> file zcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'ZCAPLUS' ENTERED AT 14:45:44 ON 28 AUG 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 28 Aug 2007 VOL 147 ISS 10

FILE LAST UPDATED: 27 Aug 2007 (20070827/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 99 L3

=> L4 and (tumor? or cancer? or hyperprolifer? or neoplas?)

L4 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s L4 and (tumor? or cancer? or hyperprolifer? or neoplas?)

481852 TUMOR?

343513 CANCER?

3132 HYPERPROLIFER?

507305 NEOPLAS?

L5 7 L4 AND (TUMOR? OR CANCER? OR HYPERPROLIFER? OR NEOPLAS?)

=> d his

(FILE 'HOME' ENTERED AT 14:44:30 ON 28 AUG 2007)

FILE 'REGISTRY' ENTERED AT 14:44:57 ON 28 AUG 2007

L1 STRUCTURE UPLOADED

L2 50 S L1

L3 2632 S L1 FUL

FILE 'ZCAPLUS' ENTERED AT 14:45:44 ON 28 AUG 2007

L4 99 S L3

L5 7 S L4 AND (TUMOR? OR CANCER? OR HYPERPROLIFER? OR NEOPLAS?)

=> d l5 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 7 ANSWERS - CONTINUE? Y/(N):y

L5 ANSWER 1 OF 7 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:728632 ZCAPLUS

DOCUMENT NUMBER: 147:143451

TITLE: Preparation of dimers and adducts of phenyltriazolopyrimidines as anticancer agents

INVENTOR(S): Wu, Yanzhong; Blum, David M.; Beyer, Carl

PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA

SOURCE: PCT Int. Appl., 63pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007075465	A1	20070705	WO 2006-US48013	20061215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				


PRIORITY APPLN. INFO.:

US 2005-751166P


P 20051216

OTHER SOURCE(S): MARPAT 147:143451

GI



I



II

AB Title compds. [I; R1 = NHCHR3R5, (substituted) cycloalkyl; n = 2-4; X = Cl, F, Br; Y = O, S, CH2, NR4; L1, L2 = H, F, Cl, Br, CF3; R3 = CF3, C2F5; R4, R5 = H, alkyl; R7 = ZR9; Z = CO, NO, SO2, PO2H; R9 = H, OH, (substituted) alkyl, alkenyl], and dimers thereof, were prepared Thus,

5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine and succinic anhydride were stirred together in THF for 1 h to give 92% title compound (II). II showed cytotoxicity to COLO 205 cells with IC<sub>50</sub> = 1.9  $\mu$ M.

IT 943515-64-8P 943515-65-9P 943515-66-0P  
943515-67-1P 943515-68-2P 943515-69-3P  
943515-70-6P 943515-71-7P 943515-72-8P  
943515-73-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of dimers and adducts of phenyltriazolopyrimidines as anticancer agents)

RN 943515-64-8 ZCAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 943515-65-9 ZCAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

Double bond geometry as shown.




RN 943515-66-0 ZCAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

09/ 895,975




RN 943515-67-1 ZCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 943515-68-2 ZCAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 943515-69-3 ZCAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

09/ 895,975




RN 943515-70-6 ZCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 943515-71-7 ZCAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 943515-72-8 ZCAPLUS  
CN INDEX NAME NOT YET ASSIGNED




09/ 895,975




RN 943515-73-9 ZCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



IT 849550-05-6  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of dimers and adducts of phenyltriazolopyrimidines as anticancer agents)  
RN 849550-05-6 ZCAPLUS  
CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

## RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 7 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:701188 ZCAPLUS

DOCUMENT NUMBER: 147:102187

TITLE: Lyophilized compositions of a triazolopyrimidine compound

INVENTOR(S): Ku, M. Sherry; Huang, W. James

PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA

SOURCE: U.S. Pat. Appl. Publ., 10pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007149552	A1	20070628	US 2006-639642	20061215
WO 2007075452	A2	20070705	WO 2006-US47977	20061215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2005-751131P P 20051216

OTHER SOURCE(S): MARPAT 147:102187

AB The present invention relates to lyophilized compns. of a triazolopyrimidine compound, or a hydrate thereof, solns. useful in preparing the lyophilized compns.; methods for preparing such compns.; methods of reconstituting the same; kits containing such compns.; and uses of the compns. for the treatment of cancer. A 5-mg strength vial was lyophilized from a 2 mg/mL bulk solution using the dihydrate succinate salt of a triazolopyrimidine compound. Since the concentration of the active ingredient

alone was not adequate to produce a strong lyophile cake, mannitol at 40 mg/mL was utilized as a bulking agent and the bulk solution pH was about 4.9.


IT 849550-05-6 849550-66-9 849550-68-1  
 942273-47-4 942273-48-5 942273-49-6  
 942273-50-9 942273-51-0 942273-52-1  
 942273-53-2 942273-54-3 942273-55-4  
 942273-56-5 942273-57-6

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (lyophilized compns. of triazolopyrimidine compound)

RN 849550-05-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849550-66-9 ZCAPLUS


CN Butanedioic acid, compd. with 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (9CI) (CA INDEX NAME)

CM 1

CRN 849550-05-6

CMF C18 H18 Cl F5 N6 O

Absolute stereochemistry.



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H

RN 849550-68-1 ZCAPLUS

CN Butanedioic acid, compd. with 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine, hydrate (1:?:?) (CA INDEX NAME)


CM 1

CRN 849550-05-6

CMF C18 H18 Cl F5 N6 O

Absolute stereochemistry.

09/ 895,975



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H

RN 942273-47-4 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 849550-05-6

CMF C18 H18 Cl F5 N6 O


Absolute stereochemistry.



CM 2

CRN 64-19-7

CMF C2 H4 O2



RN 942273-48-5 ZCAPLUS

CN INDEX NAME NOT YET ASSIGNED


09/ 895,975

CM 1

CRN 849550-05-6

CMF C18 H18 Cl F5 N6 O

Absolute stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 942273-49-6 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-, (2Z)-2-butenedioate (1:?) (CA INDEX NAME)

CM 1

CRN 849550-05-6

CMF C18 H18 Cl F5 N6 O

Absolute stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4

09/ 895,975

Double bond geometry as shown.



RN 942273-50-9 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 849550-05-6

CMF C18 H18 Cl F5 N6 O


Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 942273-51-0 ZCAPLUS

CN INDEX NAME NOT YET ASSIGNED


CM 1

CRN 849550-05-6

CMF C18 H18 Cl F5 N6 O

Absolute stereochemistry.


09/ 895,975



CM 2

CRN 87-69-4  
CMF C4 H6 O6

Absolute stereochemistry.




RN 942273-52-1 ZCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 849550-05-6  
CMF C18 H18 Cl F5 N6 O


Absolute stereochemistry.



CM 2

CRN 77-92-9  
CMF C6 H8 O7

09/ 895,975



RN 942273-53-2 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-, benzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 849550-05-6

CMF C18 H18 Cl F5 N6 O


Absolute stereochemistry.



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



RN 942273-54-3 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-, compd. with L-Aspartic acid (1:?) (CA INDEX NAME)

CM 1


CRN 849550-05-6

CMF C18 H18 Cl F5 N6 O

Absolute stereochemistry.



09/ 895,975




CM 2

CRN 56-84-8

CMF C4 H7 N O4

Absolute stereochemistry. Rotation (+).



RN 942273-55-4 ZCAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 849550-05-6

CMFC18H18ClF5N6O

Absolute stereochemistry.




CM 2

CRN 611-71-2

CMF C8 H8 O3

Absolute stereochemistry. Rotation (-).

09/ 895,975




RN 942273-56-5 ZCAPLUS  
CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-, sulfate (1:1) (CA INDEX NAME)

CM 1


CRN 849550-05-6  
CMF C18 H18 Cl F5 N6 O

Absolute stereochemistry.



CM 2

CRN 7664-93-9  
CMF H2 O4 S




RN 942273-57-6 ZCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 849550-05-6  
CMF C18 H18 Cl F5 N6 O

Absolute stereochemistry.



CM 2

CRN 57-10-3

CMF C16 H32 O2

HO<sub>2</sub>C-(CH<sub>2</sub>)<sub>14</sub>-Me

L5 ANSWER 3 OF 7 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:287127 ZCAPLUS

DOCUMENT NUMBER: 146:323549

TITLE: Preparation of crystalline forms of  
 5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine salts

INVENTOR(S): Qi, Fang Fang; Ku, M. Sherry; Wu, Yanzhong; Blum, David M.

PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA

SOURCE: U.S. Pat. Appl. Publ., 19pp., Cont.-in-part of U.S. Ser. No. 950,543.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007060597	A1	20070315	US 2006-437291	20060519
US 2005090508	A1	20050428	US 2004-950543	20040924
PRIORITY APPLN. INFO.:			US 2003-505544P	P 20030924
			US 2004-950543	A2 20040924

AB The present invention relates to crystalline forms of 5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine salts; processes for the production thereof; pharmaceutical compns. thereof; and methods for inhibiting tumor growth. Thus, the triazolo[1,5-a]pyrimidin-7-amine derivative was prepared and converted to its fumarate dihydrate salt.

IT 928642-93-7P 928642-95-9P 928642-96-0P

928642-97-1P 928642-98-2P 928642-99-3P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of crystalline forms of

chloro(difluoromethylaminopropoxy)phenyltrif


09/ 895,975

luoromethylethyltriazolopyrimidinamine salts)  
RN 928642-93-7 ZCAPLUS  
CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)-, (2E)-2-butenedioate (1:?) (CA INDEX NAME)

CM 1

CRN 249648-16-6  
CMF C14 H8 Cl F6 N5


Absolute stereochemistry.



CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.




RN 928642-95-9 ZCAPLUS  
CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)-, (2E)-2-butenedioate, hydrate (1?:2) (CA INDEX NAME)

CM 1

CRN 249648-16-6  
CMF C14 H8 Cl F6 N5

Absolute stereochemistry.




09/ 895,975

CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 928642-96-0 ZCAPLUS


CN Butanedioic acid, compd. with 5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (1:?) (CA INDEX NAME)

CM 1

CRN 249648-16-6

CMF C14 H8 Cl F6 N5


Absolute stereochemistry.



CM 2

CRN 110-15-6

CMF C4 H6 O4



RN 928642-97-1 ZCAPLUS

CN Butanedioic acid, compd. with 5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine, hydrate (1:?:?) (CA INDEX NAME)


CM 1

CRN 249648-16-6

CMF C14 H8 Cl F6 N5

Absolute stereochemistry.

09/ 895,975



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H

RN 928642-98-2 ZCAPLUS


CN Benzeneacetic acid, α-hydroxy-, compd. with 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (1:?) (CA INDEX NAME)

CM 1

CRN 849550-05-6

CMF C18 H18 Cl F5 N6 O


Absolute stereochemistry.



CM 2

CRN 90-64-2

CMF C8 H8 O3



RN 928642-99-3 ZCAPLUS

CN Benzeneacetic acid, α-hydroxy-, compd. with 5-chloro-6-[2,6-difluoro-

09/ 895,975


4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine, hydrate (1:?:?) (CA INDEX NAME)

CM 1

CRN 849550-05-6

CMF C18 H18 Cl F5 N6 O


Absolute stereochemistry.



CM 2

CRN 90-64-2

CMF C8 H8 O3




IT 249648-16-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of crystalline forms of  
chloro(difluoromethylaminopropoxy)phenyltrifluoromethylethyltriazolopyrimidinamine salts)

RN 249648-16-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 849550-05-6P 928642-92-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of crystalline forms of  
chloro(difluoromethylaminopropoxy)phenyltrifluoromethylethyltriazolopyrimidinamine salts)

RN 849550-05-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 928642-92-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

L5 ANSWER 4 OF 7 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1331991 ZCAPLUS

DOCUMENT NUMBER: 146:251802

TITLE: Synthesis and SAR of [1,2,4]Triazolo[1,5-a]pyrimidines, a Class of Anticancer Agents with a Unique Mechanism of Tubulin Inhibition

AUTHOR(S): Zhang, Nan; Ayrar-Kaloustian, Semiramis; Nguyen, Thai; Afragola, Jay; Hernandez, Richard; Lucas, Judy; Gibbons, James; Beyer, Carl

CORPORATE SOURCE: Chemical and Screening Sciences, and Discovery Oncology, Wyeth Research, Pearl River, NY, 10965, USA


SOURCE: Journal of Medicinal Chemistry (2007), 50(2), 319-327

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal



LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 146:251802  
 GI



I


AB A series of [1,2,4]triazolo[1,5-a]pyrimidines I [R1 = Cl, Br; R2, R3 = H, Me; R4 = H, F, Me2N(CH2)3S, HO(CH2)4O, Me2N(CH2)3NH, etc.; R5 = H, F, Me2N(CH2)3O; R6 = H, F] was synthesized via aromatic nucleophilic substitution reactions using alcs., thiols or amines as nucleophiles, and the structure-activity relationship of the products as anticancer agents was evaluated. (1S)-2,2,2-Trifluoro-1-methylethylamino group or an achiral 2,2,2-trifluoroethylamino group is required at the 5-position to achieve high potency. On the Ph ring, both fluoro atoms, at the positions ortho to the triazolopyrimidine core, are needed for optimal activity. At the position para to the triazolopyrimidine core, on the Ph ring, the best activity is achieved with an oxygen linkage followed by a three-methylene unit, and an alkylamino or a hydroxy group. The mechanism of action for this series of triazolopyrimidines was shown to be unique in that they promoted tubulin polymerization in vitro, but did not bind competitively with paclitaxel. Instead, these compds. inhibit the binding of vincas to tubulin. Selected compds. were studied further, and it was shown that these compds. were able to overcome resistance attributed to several multidrug resistance transporter proteins. Lead compds. were shown to inhibit tumor growth in several nude mouse xenograft models, with high potency and efficacy, when dosed either orally or i.v.

IT 214633-89-3P 249648-16-6P 388060-93-3P  
 691010-93-2P 849550-72-7P 849550-78-3P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and SAR of [1,2,4]triazolo[1,5-a]pyrimidines as anticancer agents with a unique mechanism of tubulin inhibition)

RN 214633-89-3 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(2,2,2-trifluoroethyl)-6-(2,4,6-trifluorophenyl)- (CA INDEX NAME)




RN 249648-16-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)- (CA INDEX NAME)

09/ 895,975


Absolute stereochemistry.



RN 388060-93-3 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 691010-93-2 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,4-difluorophenyl)-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-72-7 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-bromo-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-78-3 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-6-(2,3,6-trifluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 849550-08-9P 849550-11-4P 849550-12-5P  
 849550-13-6P 849550-15-8P 849550-16-9P  
 849550-18-1P 849550-19-2P 849550-20-5P  
 849550-21-6P 849550-22-7P 849550-23-8P  
 849550-24-9P 849550-25-0P 849550-26-1P  
 849550-28-3P 849550-29-4P 849550-30-7P  
 849550-31-8P 849550-32-9P 849550-36-3P  
 925902-82-5P 925902-84-7P 925902-87-0P  
 925902-89-2P 925902-94-9P 925902-99-4P  
 925903-01-1P 925903-09-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis and SAR of [1,2,4]triazolo[1,5-a]pyrimidines as anticancer agents with a unique mechanism of tubulin inhibition)

RN 849550-08-9 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 6-[4-(3-aminopropoxy)-2,6-difluorophenyl]-5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-11-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[3-(ethylmethylamino)propoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-12-5 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(1-pyrrolidinyl)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-13-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(1-piperidinyl)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-15-8 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 6-[4-[3-(1-azetidiny)propoxy]-2,6-difluorophenyl]-5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-16-9 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[3-(dimethylamino)propoxy]-2-fluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-18-1 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[4-(dimethylamino)butoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-19-2 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[2-(dimethylamino)ethoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-20-5 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-21-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[[3-(dimethylamino)propyl]thio]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-22-7 ZCAPLUS

CN Ethanol, 2-[4-[5-chloro-7-[[ (1S)-2,2,2-trifluoro-1-methylethyl]amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-23-8 ZCAPLUS

CN 1-Propanol, 3-[4-[5-chloro-7-[[ (1S)-2,2,2-trifluoro-1-methylethyl]amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-24-9 ZCAPLUS

CN 1-Butanol, 4-[4-[5-chloro-7-[[ (1S)-2,2,2-trifluoro-1-methylethyl]amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-25-0 ZCAPLUS

CN 1,3-Propanediamine, N1-[4-[5-chloro-7-[[ (1S)-2,2,2-trifluoro-1-methylethyl]amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenyl]-N1,N3,N3-trimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-26-1 ZCAPLUS

CN 1,3-Propanediamine, N3-[4-[5-chloro-7-[[ (1S)-2,2,2-trifluoro-1-methylethyl]amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenyl]-N1,N1-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 849550-28-3 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-bromo-6-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 849550-29-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[4-(dimethylamino)butyl]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-30-7 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[3-[2-(dimethylamino)ethoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-31-8 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[3-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-32-9 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[3-[4-(dimethylamino)butoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-36-3 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 925902-82-5 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 925902-84-7 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-(2,2,2-trifluoroethyl)-, hydrochloride (5:7) (CA INDEX NAME)




●7/5 HCl

RN 925902-87-0 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 925902-89-2 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[3-

09/ 895,975

(dimethylamino)propoxy]-2,6-difluorophenyl]-N-(2,2,2-trifluoroethyl)-,  
hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 925902-94-9 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(4-morpholinyl)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 925902-99-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-(3-ethoxypropoxy)-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 925903-01-1 ZCAPLUS

09/ 895,975

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 6-(4-butoxy-2,6-difluorophenyl)-5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 925903-09-9 ZCAPLUS

CN 1-Pentanol, 5-[4-[5-chloro-7-[(1S)-2,2,2-trifluoro-1-methylethyl]amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenoxy]- (CA INDEX NAME)

Absolute stereochemistry.



IT 849550-05-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and SAR of [1,2,4]triazolo[1,5-a]pyrimidines as anticancer agents with a unique mechanism of tubulin inhibition)

RN 849550-05-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

28

THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS

## RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 7 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:300451 ZCAPLUS

DOCUMENT NUMBER: 142:373861

TITLE: Preparation of 6-[(substituted)phenyl]triazolopyrimidines as tubulin polymerization promoters as anticancer agents for tumors that express multiple drug resistance (MDR) or are resistant because of MDR

INVENTOR(S): Zhang, Nan; Ayral-Kaloustian, Semiramis; Nguyen, Thai Hiep; Wu, Yanzhong; Tong, Wei

PATENT ASSIGNEE(S): Wyeth Holdings Corp., USA

SOURCE: PCT Int. Appl., 134 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030775	A1	20050407	WO 2004-US30515	20040917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004276240	A1	20050407	AU 2004-276240	20040917
CA 2539252	A1	20050407	CA 2004-2539252	20040917
EP 1680425	A1	20060719	EP 2004-788820	20040917
EP 1680425	B1	20070110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004014700	A	20061114	BR 2004-14700	20040917
CN 1867569	A	20061122	CN 2004-80030200	20040917
JP 2007506744	T	20070322	JP 2006-528075	20040917
MX 2006PA03206	A	20060623	MX 2006-PA3206	20060322
NO 2006001318	A	20060421	NO 2006-1318	20060323
IN 2006KN00951	A	20070420	IN 2006-KN951	20060417
HK 1090374	A1	20070330	HK 2006-112040	20061101
PRIORITY APPLN. INFO.:			US 2003-505544P	P 20030924
			WO 2004-US30515	W 20040917
OTHER SOURCE(S):		MARPAT 142:373861		
GI				



AB This invention relates to certain 6-[(substituted)phenyl]triazolopyrimidine compds. (shown as I; variables defined below; e.g. II) or pharmaceutically acceptable salts thereof, and compns. containing said compds. or pharmaceutically acceptable salts thereof, wherein said compds. are anti-cancer agents useful for the treatment of cancer in mammals. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compds. or pharmaceutically acceptable salts thereof. The present invention relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of

said compds. and pharmaceutically acceptable salts thereof. Strong evidence is presented that these compds. bind at the vinca/peptide site of tubulin and not at the colchicine or taxane sites. Methods of preparation are claimed and .apprx.20 example preps. are included. For example, II which was prepared in 2 steps starting with reaction of 5,7-dichloro-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidine, ((1S)-2,2,2-trifluoro-1-methylethyl)amine hydrochloride and N,N-diisopropylethylamine to give 5-Chloro-6-(2,4,6-trifluorophenyl)-N-((1S)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine, which was reacted with 3-dimethylamino-1-propanol/NaH. For I: R1 = R3R5CHNH and C6-C8 cycloalkyl (un)substituted with R8; R2 = Q(CH2)nY-, 2-L1- and 6-L2-substituted phenyl; n = 2-4; X = Cl or Br; Y = O, S, CH2 or NR4; Q = -NR6R7 and -OH; L1 and L2 = H, F, Cl, Br, or CF3; R3 = CF3 or C2F5; R4 and R5 = H or C1-3 alkyl; R6 and R7 = H or C1-C3 alkyl; or R6 and R7 when optionally taken together with the N atom to which each is attached form a 4 to 6 membered saturated heterocyclic ring with 1-2 N atoms and 0-1 O atoms or 0-1 S atoms, and (un)substituted with R8; R8 = C1-C3 alkyl.

IT 849550-66-9P 849550-67-0P

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

09/ 895,975

(Preparation); PROC (Process); USES (Uses)

(drug candidate, hydration, powder XRD; preparation of 6-[(substituted)phenyl]triazolopyrimidines as tubulin polymerization promoters as anticancer agents for tumors expressing multiple drug resistance (MDR) or resistance because of MDR)

RN 849550-66-9 ZCAPLUS


CN Butanedioic acid, compd. with 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (9CI) (CA INDEX NAME)

CM 1

CRN 849550-05-6

CMF C18 H18 Cl F5 N6 O

Absolute stereochemistry.



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H

RN 849550-67-0 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 849550-05-6

CMF C18 H18 Cl F5 N6 O

Absolute stereochemistry.



09/ 895,975




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



IT 849550-68-1P 849550-69-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate, powder XRD; preparation of 6-[(substituted)phenyl]triazolopyrimidines as tubulin polymerization promoters as anticancer agents for tumors expressing multiple drug resistance (MDR) or resistance because of MDR)

RN 849550-68-1 ZCAPLUS


CN Butanedioic acid, compd. with 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine, hydrate (1:?:?) (CA INDEX NAME)

CM 1

CRN 849550-05-6

CMF C18 H18 Cl F5 N6 O

Absolute stereochemistry.



CM 2

09/ 895,975

CRN 110-15-6  
CMF C4 H6 O4


HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H

RN 849550-69-2 ZCAPLUS  
CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-, (2E)-2-butenedioate (1:1), dihydrate (9CI) (CA INDEX NAME)

CM 1

CRN 849550-05-6  
CMF C18 H18 Cl F5 N6 O


Absolute stereochemistry.



CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.




IT 849550-04-5P, 5-Chloro-6-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-05-6P, 5-Chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-36-3P, 5-Chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-65-8P, 5-Chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine hydrochloride  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; preparation of 6-[(substituted)phenyl]triazolopyrimidines as tubulin polymerization promoters as anticancer agents for tumors expressing multiple drug resistance (MDR) or resistance because of MDR)

RN 849550-04-5 ZCAPLUS  
CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[3-

09/ 895,975

(dimethylamino)propoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-05-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-36-3 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-65-8 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 849550-06-7P, 5-Chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-(2,2,2-trifluoroethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-07-8P, 5-Chloro-6-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-N-(2,2,2-trifluoroethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-08-9P, 6-[4-(3-Aminopropoxy)-2,6-difluorophenyl]-5-chloro-N-((1S)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-09-0P, 5-Chloro-6-[2,6-difluoro-4-[3-(4-methylpiperazin-1-yl)propoxy]phenyl]-N-((1S)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-10-3P, 5-Chloro-6-[4-[3-(ethylamino)propoxy]-2,6-difluorophenyl]-N-((1S)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-11-4P, 5-Chloro-6-[4-[3-[ethyl(methyl)amino]propoxy]-2,6-difluorophenyl]-N-((1S)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-12-5P, 5-Chloro-6-[2,6-difluoro-4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-N-((1S)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-13-6P, 5-Chloro-6-[2,6-difluoro-4-[3-(piperidin-1-yl)propoxy]phenyl]-N-((1S)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-14-7P, 5-Chloro-6-[2,6-difluoro-4-[3-(morpholin-4-yl)propoxy]phenyl]-N-((1S)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-15-8P, 6-[4-[3-(Azetidin-1-yl)propoxy]-2,6-difluorophenyl]-5-chloro-N-((1S)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-16-9P, 5-Chloro-6-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-N-((1S)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-17-0P, 5-Chloro-6-[2,6-difluoro-4-[2-(methylamino)ethoxy]phenyl]-N-((1S)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-18-1P, 5-Chloro-6-[4-[4-(dimethylamino)butoxy]-2,6-difluorophenyl]-N-((1S)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-19-2P, 5-Chloro-6-[4-[2-(dimethylamino)ethoxy]-2,6-difluorophenyl]-N-((1S)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-20-5P, 5-Chloro-6-[2,6-difluoro-4-[2-(morpholin-4-yl)ethoxy]phenyl]-N-((1S)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-21-6P, 5-Chloro-6-[4-[3-(dimethylamino)propyl]thio]-2,6-difluorophenyl]-N-((1S)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-22-7P, 2-[4-[5-Chloro-7-(((1S)-2,2,2-trifluoro-1-methylethyl)amino)-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenoxy]ethanol 849550-23-8P, 3-[4-[5-Chloro-7-(((1S)-2,2,2-trifluoro-1-methylethyl)amino)-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenoxy]propan-1-ol 849550-24-9P, 4-[4-[5-Chloro-7-(((1S)-2,2,2-trifluoro-1-methylethyl)amino)-

[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenoxy]butan-1-ol  
 849550-25-OP, N-[4-[5-Chloro-7-[(1S)-2,2,2-trifluoro-1-methylethyl]amino]-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenyl]-N,N',N'-trimethylpropane-1,3-diamine 849550-26-1P  
 , N-[4-[5-Chloro-7-[(1S)-2,2,2-trifluoro-1-methylethyl]amino]-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenyl]-N',N'-dimethylpropane-1,3-diamine 849550-27-2P, N-[4-[5-Chloro-7-[(1S)-2,2,2-trifluoro-1-methylethyl]amino]-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenyl]-N',N'-dimethylethane-1,2-diamine  
 849550-28-3P, 5-Bromo-6-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-29-4P, 5-Chloro-6-[4-[4-(dimethylamino)butyl]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-30-7P  
 , 5-Chloro-6-[3-[2-(dimethylamino)ethoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-31-8P, 5-Chloro-6-[3-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-32-9P, 5-Chloro-6-[3-[4-(dimethylamino)butoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-37-4P  
 , 5-Chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-38-5P, 5-Chloro-6-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-39-6P, 6-[4-(3-Aminopropoxy)-2,6-difluorophenyl]-5-chloro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-40-9P,  
 5-Chloro-6-[2,6-difluoro-4-[3-(4-methylpiperazin-1-yl)propoxy]phenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-41-OP, 5-Chloro-6-[4-[3-(ethylamino)propoxy]-2,6-difluorophenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-42-1P, 5-Chloro-6-[4-[3-[ethyl(methyl)amino]propoxy]-2,6-difluorophenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-43-2P  
 , 5-Chloro-6-[2,6-difluoro-4-[3-(pyrrolidin-1-yl)propoxy]phenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-44-3P, 5-Chloro-6-[2,6-difluoro-4-[3-(piperidin-1-yl)propoxy]phenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-45-4P,  
 5-Chloro-6-[2,6-difluoro-4-[3-(morpholin-4-yl)propoxy]phenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-46-5P, 6-[4-[3-(Azetidin-1-yl)propoxy]-2,6-difluorophenyl]-5-chloro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-47-6P, 5-Chloro-6-[4-[3-(dimethylamino)propoxy]-2-fluorophenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-48-7P  
 , 5-Chloro-6-[2,6-difluoro-4-[2-(methylamino)ethoxy]phenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-49-8P, 5-Chloro-6-[4-[4-(dimethylamino)butoxy]-2,6-difluorophenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-50-1P, 5-Chloro-6-[4-[2-(dimethylamino)ethoxy]-2,6-difluorophenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-51-2P  
 , 5-Chloro-6-[2,6-difluoro-4-[2-(morpholin-4-yl)ethoxy]phenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-52-3P, 5-Chloro-6-[4-[3-(dimethylamino)propyl]thio]-2,6-difluorophenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-53-4P, 2-[4-[5-Chloro-7-[(1R)-2,2,2-trifluoro-1-methylethyl]amino]-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenoxy]ethanol 849550-54-5P, 3-[4-[5-Chloro-7-[(1R)-


2,2,2-trifluoro-1-methylethyl)amino]-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenoxy]propan-1-ol 849550-55-6P,  
 4-[4-[5-Chloro-7-[(1R)-2,2,2-trifluoro-1-methylethyl)amino]-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenoxy]butan-1-ol  
 849550-56-7P, N-[4-[5-Chloro-7-[(1R)-2,2,2-trifluoro-1-methylethyl)amino]-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenyl]-N,N',N'-trimethylpropane-1,3-diamine 849550-57-8P  
 , N-[4-[5-Chloro-7-[(1R)-2,2,2-trifluoro-1-methylethyl)amino]-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenyl]-N',N'-dimethylpropane-1,3-diamine 849550-58-9P, N-[4-[5-Chloro-7-[(1R)-2,2,2-trifluoro-1-methylethyl)amino]-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenyl]-N',N'-dimethylethane-1,2-diamine  
 849550-59-0P, 5-Bromo-6-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-N-((1R)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-60-3P, 5-Chloro-6-[4-[4-(dimethylamino)butyl]-2,6-difluorophenyl]-N-((1R)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-61-4P  
 , 5-Chloro-6-[3-[2-(dimethylamino)ethoxy]-2,6-difluorophenyl]-N-((1R)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-62-5P, 5-Chloro-6-[3-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-N-((1R)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-63-6P, 5-Chloro-6-[3-[4-(dimethylamino)butoxy]-2,6-difluorophenyl]-N-((1R)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-64-7P  
 , 5-Chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-((1R)-2,2,2-trifluoro-1-ethylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine 849550-70-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 6-[(substituted)phenyl]triazolopyrimidines as tubulin polymerization promoters as anticancer agents for tumors expressing multiple drug resistance (MDR) or resistance because of MDR)


RN 849550-06-7 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 849550-07-8 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 849550-08-9 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 6-[4-(3-aminopropoxy)-2,6-difluorophenyl]-5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-09-0 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-10-3 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[3-(ethylamino)propoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-11-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[3-(ethylmethylamino)propoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-12-5 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(1-pyrrolidinyl)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 849550-13-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(1-piperidinyl)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 849550-14-7 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(4-morpholinyl)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 849550-15-8 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 6-[4-[3-(1-azetidiny)propoxy]-2,6-difluorophenyl]-5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-16-9 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[3-(dimethylamino)propoxy]-2-fluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-17-0 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[2-(methylamino)ethoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 849550-18-1 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[4-(dimethylamino)butoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-19-2 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[2-(dimethylamino)ethoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-20-5 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-21-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[[3-(dimethylamino)propyl]thio]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-22-7 ZCAPLUS

CN Ethanol, 2-[4-[5-chloro-7-[[1S)-2,2,2-trifluoro-1-methylethyl]amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-23-8 ZCAPLUS

CN 1-Propanol, 3-[4-[5-chloro-7-[[1S]-2,2,2-trifluoro-1-methylethyl]amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-24-9 ZCAPLUS

CN 1-Butanol, 4-[4-[5-chloro-7-[[1S]-2,2,2-trifluoro-1-methylethyl]amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-25-0 ZCAPLUS

CN 1,3-Propanediamine, N1-[4-[5-chloro-7-[[1S]-2,2,2-trifluoro-1-methylethyl]amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenyl]-N1,N3,N3-trimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-26-1 ZCAPLUS

CN 1,3-Propanediamine, N3-[4-[5-chloro-7-[[ (1S)-2,2,2-trifluoro-1-methylethyl]amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenyl]-N1,N1-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-27-2 ZCAPLUS

CN 1,2-Ethanediamine, N'-[4-[5-chloro-7-[[ (1S)-2,2,2-trifluoro-1-methylethyl]amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-28-3 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-bromo-6-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-29-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[4-(dimethylamino)butyl]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-30-7 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[3-[2-(dimethylamino)ethoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-31-8 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[3-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-32-9 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[3-[4-(dimethylamino)butoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849550-37-4 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-(2,2,2-trifluoro-1-methylethyl)- (9CI) (CA INDEX NAME)



RN 849550-38-5 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-39-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 6-[4-(3-aminopropoxy)-2,6-difluorophenyl]-5-chloro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 849550-40-9 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 849550-41-0 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[3-(ethylamino)propoxy]-2,6-difluorophenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 849550-42-1 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[3-(ethylmethylamino)propoxy]-2,6-difluorophenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-43-2 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(1-pyrrolidinyl)propoxy]phenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-44-3 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(1-piperidinyl)propoxy]phenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-45-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(4-morpholinyl)propoxy]phenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 849550-46-5 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 6-[4-[3-(1-azetidiny)propoxy]-2,6-difluorophenyl]-5-chloro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 849550-47-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[3-(dimethylamino)propoxy]-2-fluorophenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-48-7 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[2-(methylamino)ethoxy]phenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 849550-49-8 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[4-(dimethylamino)butoxy]-2,6-difluorophenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 849550-50-1 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[2-(dimethylamino)ethoxy]-2,6-difluorophenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 895,975



RN 849550-51-2 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 849550-52-3 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[[3-(dimethylamino)propyl]thio]-2,6-difluorophenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-53-4 ZCAPLUS

CN Ethanol, 2-[4-[5-chloro-7-[[[(1R)-2,2,2-trifluoro-1-methylethyl]amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-54-5 ZCAPLUS

CN 1-Propanol, 3-[4-[5-chloro-7-[[ (1R)-2,2,2-trifluoro-1-methylethyl]amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-55-6 ZCAPLUS

CN 1-Butanol, 4-[4-[5-chloro-7-[[ (1R)-2,2,2-trifluoro-1-methylethyl]amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-56-7 ZCAPLUS

CN 1,3-Propanediamine, N-[4-[5-chloro-7-[[ (1R)-2,2,2-trifluoro-1-methylethyl]amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenyl]-N,N',N'-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-57-8 ZCAPLUS

CN 1,3-Propanediamine, N'-[4-[5-chloro-7-[[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-58-9 ZCAPLUS

CN 1,2-Ethanediamine, N'-[4-[5-chloro-7-[[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-59-0 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-bromo-6-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-60-3 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[4-(dimethylamino)butyl]-2,6-difluorophenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-61-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[3-[2-(dimethylamino)ethoxy]-2,6-difluorophenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-62-5 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[3-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-63-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[3-[4-(dimethylamino)butoxy]-2,6-difluorophenyl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-64-7 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1R)-1-(trifluoromethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 849550-70-5 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-[3-(dimethylamino)propoxy]-2,6-difluorophenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.





● x HCl


IT 249648-16-6P, 5-Chloro-6-(2,4,6-trifluorophenyl)-N-((1S)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine  
 849550-72-7P, 5-Bromo-6-(2,4,6-trifluorophenyl)-N-((1S)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine  
 849550-78-3P, 5-Chloro-6-(2,3,6-trifluorophenyl)-N-((1S)-2,2,2-trifluoro-1-methylethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 6-[(substituted)phenyl]triazolopyrimidines as tubulin polymerization promoters as anticancer agents for tumors expressing multiple drug resistance (MDR) or resistance because of MDR)

RN 249648-16-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-72-7 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-bromo-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 849550-78-3 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-6-(2,3,6-trifluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:300260 ZCAPLUS

DOCUMENT NUMBER: 142:373857

TITLE: Preparation of 5-arylpyrimidines as anticancer agents  
 INVENTOR(S): Zhang, Nan; Ayral-Kaloustian, Semiramis; Nguyen, Thai Hiep

PATENT ASSIGNEE(S): Wyeth Holdings Corporation, USA

SOURCE: PCT Int. Appl., 149 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030216	A1	20050407	WO 2004-US30682	20040917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,			

SN, TD, TG

AU 2004275733	A1	20050407	AU 2004-275733	20040917
CA 2539235	A1	20050407	CA 2004-2539235	20040917
EP 1663241	A1	20060607	EP 2004-784529	20040917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004014736	A	20061121	BR 2004-14736	20040917
CN 1871009	A	20061129	CN 2004-80031581	20040917
JP 2007506746	T	20070322	JP 2006-528086	20040917
US 2005075357	A1	20050407	US 2004-950375	20040924
MX 2006PA03207	A	20060623	MX 2006-PA3207	20060322
NO 2006001319	A	20060420	NO 2006-1319	20060323
IN 2006KN00759	A	20070803	IN 2006-KN759	20060329
PRIORITY APPLN. INFO.:			US 2003-505487P	P 20030924
			WO 2004-US30682	W 20040917

OTHER SOURCE(S): CASREACT 142:373857; MARPAT 142:373857

GI




AB This invention relates to certain 5-arylpyrimidine compds. I [Z = NHCHR1R5, cycloalkyl; R = substituted Ph; X = Cl, Br; W1 = NHR6, N(CN)R6, aryl; R1 = H, alkyl; R5 = CF3, C2F5; R6 = alkyl] or a pharmaceutically acceptable salt thereof, and compns. containing said compds. or a pharmaceutically acceptable salt thereof, wherein said compds. are anti-cancer agents useful for the treatment of cancer in mammals (biol. data given). Over thirty examples describe the synthesis of compds. I. E.g., a multi-step synthesis of I [Z = NHCH2CF3; R = 2,4,6-F3C6H2; X = Cl; W1 = N(CN)Me], starting from 5,7-dichloro-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine and 2,2,2-trifluoroethylamine, was given. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of the compds. I or a pharmaceutically acceptable salt thereof. More specifically, the present invention relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of the compds. I and pharmaceutically acceptable salts thereof.

IT 214633-89-3P, 5-Chloro-6-(2,4,6-trifluorophenyl)-N-(2,2,2-trifluoroethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of 5-arylpyrimidines as anticancer agents)

RN 214633-89-3 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(2,2,2-trifluoroethyl)-6-(2,4,6-trifluorophenyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 7 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:31452 ZCAPLUS

DOCUMENT NUMBER: 136:96032

TITLE: Substituted triazolopyrimidines as anticancer agents

INVENTOR(S): Schmitt, Mark R.; Kirsch, Donald R.; Harris, Jane E.; Beyer, Carl F.; Pees, Klaus-Juergen; Carter, Paul; Pfrengle, Waldemar; Albert, Guido

PATENT ASSIGNEE(S): American Home Products Corporation, USA

SOURCE: PCT Int. Appl., 405 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002563	A2	20020110	WO 2001-US20672	20010628
WO 2002002563	A3	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2413802	A1	20020110	CA 2001-2413802	20010628
BR 2001012038	A	20030401	BR 2001-12038	20010628
EP 1307200	A2	20030507	EP 2001-952295	20010628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 200300798	A2	20030728	HU 2003-798	20010628
JP 2004502691	T	20040129	JP 2002-507815	20010628
NZ 523807	A	20040924	NZ 2001-523807	20010628
CN 1592624	A	20050309	CN 2001-812055	20010628
US 2002068744	A1	20020606	US 2001-895975	20010629
BG 107277	A	20040130	BG 2002-107277	20021115
MX 2002PA11913	A	20030422	MX 2002-PA11913	20021202
NO 200206195	A	20030227	NO 2002-6195	20021223
IN 2003KN00001	A	20050311	IN 2003-KN1	20030101
ZA 2003000793	A	20040720	ZA 2003-793	20030129
IN 2007KN00659	A	20070706	IN 2007-KN659	20070222
PRIORITY APPLN. INFO.:			US 2000-215585P	P 20000630
			WO 2001-US20672	W 20010628
			IN 2003-KN1	A3 20030101

OTHER SOURCE(S): MARPAT 136:96032

- PG Pub.


AB A method is provided for treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof which comprises administering to the mammal an effective amount of a substituted triazolopyrimidine derivative or a pharmaceutically acceptable salt thereof. Also provided is a method for treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by interacting with tubulin and microtubules and promoting microtubule polymerization which comprises administering to the mammal an effective amount of a substituted triazolopyrimidine derivative or a pharmaceutically acceptable salt thereof.

IT 150987-15-8 150987-46-5 150987-48-7  
 150987-75-0 150988-06-0 150988-18-4  
 150988-20-8 150988-28-6 214633-87-1  
 214633-88-2 214633-90-6 214633-92-8  
 214633-93-9 214633-94-0 214633-97-3  
 214634-13-6 214634-14-7 214634-21-6 21463  
 4-25-0 214634-32-9 214634-42-1  
 214634-48-7 214634-49-8 214706-54-4  
 214706-56-6 214706-62-4 214706-64-6  
 214706-66-8 214706-68-0 214706-69-1  
 214706-71-5 214706-72-6 214706-77-1  
 214706-82-8 220482-12-2 244092-09-9  
 244092-12-4 244092-19-1 244092-24-8  
 244092-25-9 244092-30-6 244092-31-7  
 244092-39-5 244092-46-4 292035-69-9  
 292035-83-7 292035-92-8 329911-38-8  
 343252-77-7 388059-99-2 388060-00-2  
 388060-07-9 388060-08-0 388060-10-4  
 388060-11-5 388060-12-6 388060-13-7  
 388060-14-8 388060-28-4 388060-29-5  
 388060-37-5 388060-40-0 388060-41-1  
 388060-42-2 388060-44-4 388060-45-5  
 388060-51-3 388060-63-7 388060-66-0  
 388060-69-3 388060-72-8 388060-74-0  
 388060-76-2 388060-78-4 388060-79-5  
 388060-80-8 388060-82-0 388060-83-1  
 388060-84-2 388060-85-3 388060-86-4  
 388060-87-5 388060-88-6 388060-93-3  
 388060-94-4 388060-95-5 388060-97-7  
 388060-99-9 388061-00-5 388061-01-6  
 388061-02-7 388061-03-8 388061-07-2  
 388061-08-3 388061-09-4 388061-11-8  
 388061-12-9 388061-13-0 388061-14-1  
 388061-16-3 388061-21-0 388061-22-1  
 388061-23-2 388061-27-6 388061-32-3  
 388061-33-4 388061-34-5 388061-35-6  
 388061-36-7 388061-37-8 388061-39-0  
 388061-41-4 388061-43-6 388061-47-0  
 388061-52-7 388061-54-9 388061-55-0  
 388061-56-1 388061-57-2 388061-58-3  
 388061-59-4 388061-60-7 388061-61-8  
 388061-62-9

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (triazolopyrimidine derivs. as anticancer agents)


RN 150987-15-8 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-cyclopentyl-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 150987-46-5 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chlorophenyl)-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 150987-48-7 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 6-[1,1'-biphenyl]-4-yl-5-chloro-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 150987-75-0 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(1-methylethyl)-6-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 150988-06-0 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-5(1H)-one, 7-(cyclopentylamino)-6-(2-fluorophenyl)-, hydrazone (9CI) (CA INDEX NAME)




RN 150988-18-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-6-fluorophenyl)-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 150988-20-8 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, N-bicyclo[2.2.1]hept-2-yl-5-chloro-6-(2-chloro-6-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 150988-28-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N,N-diethyl-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214633-87-1 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 214633-88-2 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,6-difluorophenyl)-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 214633-90-6 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chlorophenyl)-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)






RN 214633-92-8 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(2,2,2-trifluoro-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 214633-93-9 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,6-difluorophenyl)-N-(2,2,2-trifluoro-1-methylethyl)- (9CI) (CA INDEX NAME)



RN 214633-94-0 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(2,2,2-trifluoro-1-methylethyl)-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 214633-97-3 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chlorophenyl)-N-


09/ 895,975

(2,2,2-trifluoro-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 214634-13-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(2-methylpropyl)-N-(2,2,2-trifluoroethyl)-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 214634-14-7 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-methylphenyl)-N-(2-methylpropyl)-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 214634-21-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(1-methylethyl)-N-(2,2,2-trifluoroethyl)-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 214634-25-0 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-methylphenyl)-N,N-bis(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 214634-32-9 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 6-(2-bromo-5-chlorophenyl)-5-chloro-N-(2,2,2-trifluoro-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 214634-42-1 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,4,6-trifluorophenyl)-N-(2,2,2-trifluoro-1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 214634-48-7 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-[2-methyl-1-(trifluoromethyl)propyl]-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 214634-49-8 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-(2,2,2-trifluoro-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 214706-54-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 214706-56-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(1-methylethyl)-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 214706-62-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, N-bicyclo[2.2.1]hept-2-yl-5-chloro-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 214706-64-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-methyl-N-(2-methyl-2-propenyl)-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 214706-66-8 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,4,6-trifluorophenyl)-N-(1,2,2-trimethylpropyl)- (9CI) (CA INDEX NAME)



RN 214706-68-0 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(2-methylpropyl)-N-2-

propenyl-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 214706-69-1 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(1,2-dimethylpropyl)-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 214706-71-5 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(1-phenylethyl)-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 214706-72-6 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-ethyl-N-(2-methylpropyl)-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



09/ 895,975


RN 214706-77-1 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(1,2-dimethylpropyl)-N-methyl-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 214706-82-8 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-[1-(4-methylphenyl)ethyl]-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 220482-12-2 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 6-(2-chloro-6-fluorophenyl)-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 244092-09-9 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 244092-12-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-cyclopentyl-6-(2,6-difluoro-4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 244092-19-1 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-ethyl-N-(2-methyl-2-propenyl)- (9CI) (CA INDEX NAME)



RN 244092-24-8 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-(2-fluoroethoxy)phenyl]-N-(2,2,2-trifluoro-1-methylethyl)- (9CI) (CA INDEX NAME)





RN 244092-25-9 ZCAPLUS

Absolute stereochemistry.



RN 244092-30-6 ZCAPLUS


CCOCOCOCc1cc(F)c2c(c1)c(Cl)c3nc(NC(C)C(F)(F)F)n3

RN 244092-31-7 ZCAPLUS

COCCOCCOC1=CC=C(C=C1F)C2=C(C=C(C=C2N3C=NC(=C3N)N)Cl)F


RN 244092-39-5 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-(2,2,2-trifluoroethoxy)phenyl]-N-(2,2,2-trifluoro-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 244092-46-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-6-fluoro-4-methoxyphenyl)-N-(2,2,2-trifluoro-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 292035-69-9 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(2,3,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 292035-83-7 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(3-chloropropyl)-N-methyl-6-(2,3,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



09/ 895,975


RN 292035-92-8 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(1-methylethyl)-6-(2,3,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 329911-38-8 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,4-difluorophenyl)-N-(2,2,2-trifluoro-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 343252-77-7 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,6-dichloro-4-fluorophenyl)-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 388059-99-2 ZCAPLUS

CN Glycine, N-[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]-N-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 388060-00-2 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(1,1,3,3-tetramethylbutyl)- (9CI) (CA INDEX NAME)




RN 388060-07-9 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-6-fluorophenyl)-N-ethyl-N-(2-methyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 388060-08-0 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-6-fluorophenyl)-N-[(2,2-dichlorocyclopropyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 388060-10-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, N-bicyclo[2.2.1]hept-2-yl-5-chloro-6-(3-chloro-4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 388060-11-5 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,5-difluorophenyl)-N-dodecyl- (9CI) (CA INDEX NAME)




RN 388060-12-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(2-methyl-2-propenyl)-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 388060-13-7 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-6-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 388060-14-8 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(3-chloro-4-methoxyphenyl)-N-cycloheptyl- (9CI) (CA INDEX NAME)




RN 388060-28-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 6-(2-bromophenyl)-5-chloro-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 388060-29-5 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-ethyl-6-(4-methoxyphenyl)-N-(2-methyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 388060-37-5 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 388060-40-0 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 388060-41-1 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-ethyl-6-(2-methoxyphenyl)-N-(2-methyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 388060-42-2 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-6-fluorophenyl)-N-hexyl- (9CI) (CA INDEX NAME)




RN 388060-44-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 388060-45-5 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(1-methylpropyl)-6-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 388060-51-3 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-dichloro-4-




09/ 895,975

(trifluoromethyl)phenyl]-N-ethyl-N-(2-methyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 388060-63-7 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-6-fluorophenyl)-N-hexyl-N-2-propenyl- (9CI) (CA INDEX NAME)



RN 388060-66-0 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(cyclopropylmethyl)-N-propyl- (9CI) (CA INDEX NAME)



RN 388060-69-3 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(4-chloro-2,3,5,6-tetrafluorophenyl)-N-cyclopentyl- (9CI) (CA INDEX NAME)

09/ 895,975




RN 388060-72-8 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-4-nitrophenyl)-N-ethyl-N-(2-methyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 388060-74-0 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-cyclopentyl-6-(4-ethoxy-2,3,5,6-tetrafluorophenyl)- (9CI) (CA INDEX NAME)




RN 388060-76-2 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, N-butyl-5-chloro-N-ethyl-6-(pentafluorophenyl)- (9CI) (CA INDEX NAME)




RN 388060-78-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(1,2,2-trimethylpropyl)- (9CI) (CA INDEX NAME)




RN 388060-79-5 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(pentafluorophenyl)-N-(1,2,2-trimethylpropyl)- (9CI) (CA INDEX NAME)



RN 388060-80-8 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(4-fluorophenyl)-N-(1,2,2-trimethylpropyl)- (9CI) (CA INDEX NAME)



09/ 895,975


RN 388060-82-0 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-methylphenyl)-N-(1,2,2-trimethylpropyl)- (9CI) (CA INDEX NAME)




RN 388060-83-1 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,4,5-trifluorophenyl)-N-(1,2,2-trimethylpropyl)- (9CI) (CA INDEX NAME)




RN 388060-84-2 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 6-(2-bromophenyl)-5-chloro-N-(1,2,2-trimethylpropyl)- (9CI) (CA INDEX NAME)




RN 388060-85-3 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-methyl-N-(1-methylethyl)-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 388060-86-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-cyclopentyl-N-methyl-6-(pentafluorophenyl)- (9CI) (CA INDEX NAME)




RN 388060-87-5 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(1,2-dimethylpropyl)-N-methyl-6-(pentafluorophenyl)- (9CI) (CA INDEX NAME)



RN 388060-88-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)




09/ 895,975

RN 388060-93-3 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 388060-94-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,6-dichloro-4-fluorophenyl)-N-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)




RN 388060-95-5 ZCAPLUS

CN Phenol, 4-[5-chloro-7-[(2,2,2-trifluoro-1-methylethyl)amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-2,5-difluoro- (9CI) (CA INDEX NAME)




RN 388060-97-7 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-(1,2-dimethylpropyl)- (9CI) (CA INDEX NAME)




RN 388060-99-9 ZCAPLUS

CN Hexanoic acid, 6-[4-[5-chloro-7-[(2,2,2-trifluoro-1-methylethyl)amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluorophenoxy]- (9CI) (CA INDEX NAME)




RN 388061-00-5 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(1-methylethyl)-6-[2-[(trifluoromethyl)thio]phenyl]- (9CI) (CA INDEX NAME)




RN 388061-01-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-[4-(trifluoromethyl)phenyl]-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 388061-02-7 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(4,4,4-trifluoro-2-methylbutyl)-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 388061-03-8 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-(3-methyl-3-butenyl)- (9CI) (CA INDEX NAME)



RN 388061-07-2 ZCAPLUS


CN Phenol, 4-[5-chloro-7-[(2,2,2-trifluoro-1-methylethyl)amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluoro- (9CI) (CA INDEX NAME)






RN 388061-08-3 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-(3-furanylmethoxy)phenyl]-N-(2,2,2-trifluoro-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 388061-09-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,5-difluoro-4-methoxyphenyl)-N-(1,2-dimethylpropyl)- (9CI) (CA INDEX NAME)




RN 388061-11-8 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-(2-fluoroethoxy)phenyl]-N-ethyl-N-(2-methyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 388061-12-9 ZCAPLUS

CN Ethanol, 2-[2-[3-chloro-4-[5-chloro-7-[(2,2,2-trifluoro-1-methylethyl)amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-5-fluorophenoxy]ethoxy]- (9CI) (CA INDEX NAME)




RN 388061-13-0 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,3-difluoro-4-methoxyphenyl)-N-(2,2,2-trifluoro-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 388061-14-1 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-6-fluorophenyl)-N-[(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 388061-16-3 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(1-ethylpentyl)- (9CI) (CA INDEX NAME)




RN 388061-21-0 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,4-dichlorophenyl)-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 388061-22-1 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, N-bicyclo[2.2.1]hept-2-yl-5-chloro-6-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 388061-23-2 ZCAPLUS

CN 1,4-Dioxo-8-azaspiro[4.5]decan-8-amine, N-[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 388061-27-6 ZCAPLUS

CN 1,4-Dioxo-8-azaspiro[4.5]decan-8-amine, N-[5-chloro-6-(4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 388061-32-3 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(3,4-difluorophenyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 388061-33-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-bromo-6-(4-bromophenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 388061-34-5 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-bromo-N,N-dimethyl-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



09/ 895,975


RN 388061-35-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(3,4-difluorophenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 388061-36-7 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-ethyl-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 388061-37-8 ZCAPLUS

CN Glycine, N-[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 388061-39-0 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2,5-difluorophenyl)-N-(3-methyl-3-butenyl)- (9CI) (CA INDEX NAME)




RN 388061-41-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N,N-diethyl-6-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 388061-43-6 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 388061-47-0 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(4-methyl-3-nitrophenyl)-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 388061-52-7 ZCAPLUS  
 CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-(2-chloro-6-fluorophenyl)-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 388061-54-9 ZCAPLUS  
 CN 1,5-Pentanediamine, N'-[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 388061-55-0 ZCAPLUS  
 CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-(3-methyl-3-butenyl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 388061-56-1 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidine-5,7-diamine, N7-cyclopentyl-N5,N5-dimethyl-6-phenyl- (9CI) (CA INDEX NAME)



RN 388061-57-2 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-[(2,2-dichlorocyclopropyl)methyl]-6-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 388061-58-3 ZCAPLUS


CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-ethyl-6-(2-methylphenyl)- (9CI) (CA INDEX NAME)






RN 388061-59-4 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[4-(1,1-dimethylethyl)phenyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 388061-60-7 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[(3-methyl-3-butenyl)oxy]phenyl]-N-(2,2,2-trifluoro-1-methylethyl)- (9CI) (CA INDEX NAME)



RN 388061-61-8 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-(1-propenyloxy)phenyl]-N-(2,2,2-trifluoro-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 388061-62-9 ZCAPLUS

CN [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-N-tricyclo[2.2.1.0(2,6)]hept-1-yl-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

09/ 895,975

NAME)



=> file caold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

47.33

219.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-5.46

-5.46

FILE 'CAOLD' ENTERED AT 14:47:59 ON 28 AUG 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 14:44:30 ON 28 AUG 2007)

FILE 'REGISTRY' ENTERED AT 14:44:57 ON 28 AUG 2007

L1 STRUCTURE UPLOADED

L2 50 S L1

L3 2632 S L1 FUL

FILE 'ZCAPLUS' ENTERED AT 14:45:44 ON 28 AUG 2007

L4 99 S L3

L5 7 S L4 AND (TUMOR? OR CANCER? OR HYPERPROLIFER? OR NEOPLAS?)

FILE 'CAOLD' ENTERED AT 14:47:59 ON 28 AUG 2007